Position in LLY
as of Jun 30, 2026
· filed Jul 24, 2026
Position Value
$57,572
+$15,263 QoQ
Shares Held
48
+4.3% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.06%
of 13F equity value
Holder Rank
#4,523
of 4,605 holders
Holding Since
Jun 2020
7 quarters on record
Voting authority
Sole 0%
Shared 100%
None 0%
Common Shares in LLY Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026AlphaCentric Advisors LLC holds $8,379,594 across 8 Drug Manufacturers - General names. LLY ranks #8 (0.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | GILD |
Gilead Sciences, Inc.
|
20,426 | $2,580,620 | |
| 2 | AZN |
Astrazeneca PLC
|
11,394 | $2,160,530 | |
| 3 | ABBV |
AbbVie Inc.
|
3,613 | $909,175 | |
| 4 | AMGN |
Amgen Inc
|
2,362 | $855,327 | |
| 5 | BIIB |
Biogen Inc.
|
3,891 | $840,689 | |
| 6 | SNY |
Sanofi
|
14,590 | $622,409 | |
| 7 | JNJ |
Johnson & Johnson
|
1,391 | $353,272 | |
| 8 | LLY |
ELI LILLY & Co
This page
|
48 | $57,572 |
All Filings in LLY
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $57,572 | 48 | Shares | Other | 2026-07-24 | |
| 2026-03-31 | $42,309 | 46 | Shares | Other | 2026-05-07 | |
| 2024-12-31 | $4,740,080 | 6,140 | Shares | Other | 2025-01-31 | |
| 2021-03-31 | $52,870 | 283 | Shares | Other | 2022-03-09 | |
| 2020-12-31 | $49,301 | 292 | Shares | Other | 2022-03-11 | |
| 2020-09-30 | $46,774 | 316 | Shares | Other | 2022-03-11 | |
| 2020-06-30 | $56,477 | 344 | Shares | Other | 2022-03-11 | |
| No filing history on record for this holder in this stock. | ||||||